Drug Type Biological products |
Synonyms |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), Siglec-15 inhibitors(Sialic acid-binding Ig-like lectin 15 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | 30 Nov 2021 |